Send to

Choose Destination
See comment in PubMed Commons below
Clin Ophthalmol. 2007 Sep;1(3):273-84.

Intravitreal bevacizumab: an analysis of the evidence.

Author information

  • 1Division of Ophthalmology, Faculty of Health Sciences, University of Stellenbosch, Western Cape, South Africa.



To review the English language publications addressing the effect of intravitreal bevacizumab (IVB) injection in a variety of eye conditions and analyze the data where possible.


Examination of data obtained using a Pubmed literature search conducted mid May 2007 with the keywords "intravitreal bevacizumab".


A dose of 1.25 mg was used in 89.5% of 965 age-related macular degeneration (ARMD) cases with 47% receiving intravitreal bevacizumab as primary therapy. In 829 patients receiving repeated doses of 1.25 mg the mean logMAR best-corrected visual acuity (BCVA) improved from 0.88 at baseline to 0.74 at 4-6 weeks, 0.71 at 8-10 weeks, 0.67 at 12-14 weeks and 0.86 at >14 weeks. Mean central retinal thickness (CRT) decreased by 83.71 mum at 4-6 weeks, 79.52 mum at 8-10 weeks, 92.46 mum at 12-14 weeks, and 75.64 mum at >14 weeks respectively. In 64 patients receiving IVB for retinal vein occlusion (RVO) mean logMAR BCVA decreased from 1.21 at baseline to 0.83 and 0.82 at 4 and 12 weeks respectively. Mean CRT decreased from 635.97 mum at baseline to 320.06 mum and 346.27 mum at 4 and 12 weeks. Favorable responses have been reported in various other conditions.


Current evidence suggests that intravitreal bevacizumab, alone or as an adjunct to conventional therapy, has a beneficial effect in various neovascular and edematous retinal conditions and is well tolerated in the short term.


bevacizumab; intravitreal; review

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk